Literature DB >> 36175824

Investigating a Genetic Link Between Alzheimer's Disease and CADASIL-Related Cerebral Small Vessel Disease.

Paul J Dunn1,2, Rodney A Lea1, Neven Maksemous1, Robert A Smith1, Heidi G Sutherland1, Larisa M Haupt1, Lyn R Griffiths3.   

Abstract

Monogenic forms of Alzheimer's disease (AD) have been identified through mutations in genes such as APP, PSEN1, and PSEN2, whilst other genetic markers such as the APOE ε carrier allele status have been shown to increase the likelihood of having the disease. Mutations in these genes are not limited to AD, as APP mutations can also cause an amyloid form of cerebral small vessel disease (CSVD) known as cerebral amyloid angiopathy, whilst PSEN1 and PSEN2 are involved in NOTCH3 signalling, a process known to be dysregulated in the monogenic CSVD, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). The overlap between AD genes and causes of CSVD led to the hypothesis that mutations in other genes within the PANTHER AD-presenilin pathway may be novel causes of CSVD in a cohort of clinically suspicious CADASIL patients without a pathogenic NOTCH3 mutation. To investigate this, whole exome sequencing was performed on 50 suspected CADASIL patients with no NOTCH3 mutations, and a targeted gene analysis was completed on the PANTHER. ERN1 was identified as a novel candidate CSVD gene following predicted pathogenic gene mutation analysis. Rare variant burden testing failed to identify an association with any gene; however, it did show a nominally significant link with ERN1 and TRPC3. This study provides evidence to support a genetic overlap between CSVD and Alzheimer's disease.
© 2022. The Author(s).

Entities:  

Keywords:  Alzheimer’s disease; Burden test; CADASIL; Cerebral small vessel disease; Whole exome sequencing

Year:  2022        PMID: 36175824     DOI: 10.1007/s12035-022-03039-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  52 in total

1.  The minimum prevalence of CADASIL in northeast England.

Authors:  S K Narayan; G Gorman; R N Kalaria; G A Ford; P F Chinnery
Journal:  Neurology       Date:  2012-03-14       Impact factor: 9.910

2.  Bare rudiments of notch signaling: how receptor levels are regulated.

Authors:  Jing Wu; Emery H Bresnick
Journal:  Trends Biochem Sci       Date:  2007-10       Impact factor: 13.807

3.  Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients.

Authors:  A Joutel; K Vahedi; C Corpechot; A Troesch; H Chabriat; C Vayssière; C Cruaud; J Maciazek; J Weissenbach; M G Bousser; J F Bach; E Tournier-Lasserve
Journal:  Lancet       Date:  1997-11-22       Impact factor: 79.321

4.  Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.

Authors:  A Joutel; C Corpechot; A Ducros; K Vahedi; H Chabriat; P Mouton; S Alamowitch; V Domenga; M Cécillion; E Marechal; J Maciazek; C Vayssiere; C Cruaud; E A Cabanis; M M Ruchoux; J Weissenbach; J F Bach; M G Bousser; E Tournier-Lasserve
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

5.  Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries.

Authors:  E J Belin de Chantemèle; K Retailleau; F Pinaud; E Vessières; A Bocquet; A L Guihot; B Lemaire; V Domenga; C Baufreton; L Loufrani; A Joutel; D Henrion
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-25       Impact factor: 8.311

Review 6.  Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.

Authors:  Tamas Revesz; Janice L Holton; Tammaryn Lashley; Gordon Plant; Blas Frangione; Agueda Rostagno; Jorge Ghiso
Journal:  Acta Neuropathol       Date:  2009-02-19       Impact factor: 17.088

Review 7.  The γ-secretase complex: from structure to function.

Authors:  Xian Zhang; Yanfang Li; Huaxi Xu; Yun-Wu Zhang
Journal:  Front Cell Neurosci       Date:  2014-12-11       Impact factor: 5.505

8.  Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL.

Authors:  Julie W Rutten; Hans G Dauwerse; Gido Gravesteijn; Martine J van Belzen; Jeroen van der Grond; James M Polke; Manuel Bernal-Quiros; Saskia A J Lesnik Oberstein
Journal:  Ann Clin Transl Neurol       Date:  2016-09-28       Impact factor: 4.511

Review 9.  Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects.

Authors:  Ilaria Di Donato; Silvia Bianchi; Nicola De Stefano; Martin Dichgans; Maria Teresa Dotti; Marco Duering; Eric Jouvent; Amos D Korczyn; Saskia A J Lesnik-Oberstein; Alessandro Malandrini; Hugh S Markus; Leonardo Pantoni; Silvana Penco; Alessandra Rufa; Osman Sinanović; Dragan Stojanov; Antonio Federico
Journal:  BMC Med       Date:  2017-02-24       Impact factor: 8.775

10.  Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology.

Authors:  M Mancuso; M Arnold; A Bersano; A Burlina; H Chabriat; S Debette; C Enzinger; A Federico; A Filla; J Finsterer; D Hunt; S Lesnik Oberstein; E Tournier-Lasserve; H S Markus
Journal:  Eur J Neurol       Date:  2020-03-20       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.